Navigation Links
Orexigen(R) Therapeutics Releases New Efficacy Data for Contrave(R) in Late Breaker Presentations at the 27th Annual Scientific Meeting of The Obesity Society
Date:10/27/2009

r suicidal ideation and there was no evidence of abuse dependence.

The Company is on track to submit a New Drug Application (NDA) for Contrave with the FDA in the first half of 2010.

About Orexigen® Therapeutics

Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on developing therapies that offer multiple approaches to treating obesity. The Company's lead investigational product, Contrave®, has completed the COR clinical development program and is on track for a regulatory submission with the FDA in the first half of 2010. The Company's second obesity drug candidate, Empatic(TM) has completed Phase 2 trials. Each product candidate is designed to act on a specific group of neurons in the central nervous system with the goal of achieving appetite suppression and sustained weight loss, through combination therapeutic approaches. Further information about the Company can be found at http://www.Orexigen.com.

Forward-Looking Statements

Orexigen cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "indicates," "will," "intends," "potential," "suggests," "assuming," "designed" and similar expressions are intended to identify forward-looking statements. These statements are based on the Company's current beliefs and expectations. These forward-looking statements include statements regarding the efficacy and safety of Empatic(TM) and Contrave®, the potential for, and timing of, proceeding to Phase 3 clinical trials for Empatic or filing an NDA for Contrave, the commercial and therapeutic potential of Empatic and Contrave, and the potential to obtain regulatory approval for, and effectively treat obesity with, either product candidate. The inclusion of forward-looking statements
'/>"/>

SOURCE Orexigen Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Orexigen(R) Initiates Second Phase IIb Empatic(TM) Trial on Schedule
2. Orexigen(R) Therapeutics Presents Data on Its Proprietary Formulation of Naltrexone Sustained Release (SR) Used in Contrave(R)
3. Orexigen(R) Therapeutics Announces Changes to Its Clinical Programs and Management Team
4. Orexigen(R) Therapeutics Schedules July 20, 2009 Teleconference and Webcast Discussion of Contrave(R) Phase 3 Results
5. Orexigen(R) Therapeutics Schedules September 30, 2009 Teleconference and Webcast to Discuss Phase 2b Trial Results From Second Obesity Drug Candidate, Empatic(TM)
6. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
7. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
8. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
9. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
10. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
11. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... WAYNE, Pa. , July 31, 2015 /PRNewswire/ ... a fully integrated specialty pharmaceutical company focused on ... announced the closing of its previously announced underwritten ... stock at a public offering price of $11.25 ... the offering included 1,000,000 shares issued upon the ...
(Date:7/31/2015)... 31, 2015 According to a ... Product (Bioimpedance Analyzers (BIA), Dual-Energy X-ray Absorptiometry (DEXA), Skinfold ... Global Analysis & Forecast to 2019", published by MarketsandMarkets, ... $911.1 Million 2014 and is estimated to grow to ... 9.4% from 2014 to 2019. Browse ...
(Date:7/30/2015)... SAN DIEGO , July 30, 2015 ... announced it has signed a definitive agreement ... provider of non-invasive ventilation and sleep-disordered breathing ... strong clinical, innovation and market reputation in China, combined with ResMed,s global leadership ... of people in China ...
Breaking Medicine Technology:Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 2Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 3Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 4Body Composition Analyzers Market Worth $1,425.7 Million by 2019 2Body Composition Analyzers Market Worth $1,425.7 Million by 2019 3Body Composition Analyzers Market Worth $1,425.7 Million by 2019 4ResMed Invests in High-Growth Chinese Sleep and Respiratory Care Market with Curative Medical 2ResMed Invests in High-Growth Chinese Sleep and Respiratory Care Market with Curative Medical 3
(Date:8/1/2015)... ... August 01, 2015 , ... Tina Wilcoxson, owner of Freeport Maine’s Royal ... that honor by the National Retail Federation, the largest retail trade association in the ... three Maine business owners to be named as such. According to the NRF’s website, ...
(Date:8/1/2015)... ... 01, 2015 , ... BeverlyD, owner and founder of BeverlyD Luxe Organic Hair ... first small business donation to kick off the campaign for healing and Well-Being. , ... includes a complete line of raw, organic hair care products, as well as her ...
(Date:7/31/2015)... ... , ... When the weather turned hot and warm-season turfgrasses, such as zoysia ... Leisure Time(TM) zoysia . It's nicknamed LTZ(TM) for short. Incidentally, both names are ... type of sod, Super-Sod is giving away red Adirondack chairs with the Leisure Time ...
(Date:7/31/2015)... ... July 31, 2015 , ... Recently touted by Becker’s ... predictive health analytics , Jvion continues to disrupt the predictive analytic and big ... targets patient and population level illness to drive prevention and better health outcomes. ...
(Date:7/31/2015)... ... 2015 , ... Jacksonville-based drug and alcohol rehabilitation center, Lakeview ... The medical community, social workers, law enforcement, and government officials are all invited ... effort to better understand and combat sex trafficking. Lead by sex trafficking expert ...
Breaking Medicine News(10 mins):Health News:Local Retail Advocate Wins National Recognition 2Health News:March4thforWellBeing Foundation Kickoff 2Health News:Super-Sod Introduces Leisure Time(TM) Zoysia Grass with an Adirondack Chair Promotion 2Health News:Jvion Showcased as Leader in the Predictive Analytic Market 2Health News:Lakeview Health Links Sex Trafficking and Addiction in Special Jacksonville Educational Workshop 2Health News:Lakeview Health Links Sex Trafficking and Addiction in Special Jacksonville Educational Workshop 3
... a Patient-Centered Medical Home Popular with Patients and ... of Ontario,s Family Health Team Model, which serves ... largest example of a patient-centered medical home. Implemented ... based on multidisciplinary teams and an innovative incentive-based ...
... MONDAY, March 14 (HealthDay News) -- Stroke survivors, even ... be independent if they are depressed, older, or have other ... stroke survivors, average age 62, who had no severe language ... with depression one month after their stroke. The patients, ...
... HealthDay Reporter , MONDAY, March 14 (HealthDay News) ... and use physical punishment, even on tots who are still ... 1-year-olds found they were more likely to spank and less ... The finding adds more weight to the emerging awareness of ...
... By Alan Mozes HealthDay Reporter , MONDAY, ... -- and the abundance of omega-3 fatty acids found in ... age-related macular degeneration (AMD), new research suggests. This latest ... health mirrors past research that has found the same benefit. ...
... Goodwin HealthDay Reporter , MONDAY, March 14 (HealthDay News) ... pediatrician or nurse they see regularly who offers comprehensive care -- ... new research finds. Yet it,s the sickest children -- those ... most care -- who are less likely to get the sort ...
... In a research study appearing in the journal Cancer ... Laboratory (CSHL) and four other institutions have identified a strategy ... limited treatment options and one of the worst one-year survival ... up to 15% of liver tumors are "driven" by the ...
Cached Medicine News:Health News:March/April 2011 Annals of Family Medicine tip sheet 2Health News:March/April 2011 Annals of Family Medicine tip sheet 3Health News:March/April 2011 Annals of Family Medicine tip sheet 4Health News:March/April 2011 Annals of Family Medicine tip sheet 5Health News:March/April 2011 Annals of Family Medicine tip sheet 6Health News:March/April 2011 Annals of Family Medicine tip sheet 7Health News:March/April 2011 Annals of Family Medicine tip sheet 8Health News:Depression Threatens Independence of Stroke Survivors 2Health News:Depressed Dads More Likely to Spank, Shortchange Kids: Study 2Health News:Depressed Dads More Likely to Spank, Shortchange Kids: Study 3Health News:Eating Fish Might Protect Your Eyesight 2Health News:Eating Fish Might Protect Your Eyesight 3Health News:'Medical Homes' Help Kids Get Comprehensive Care 2Health News:'Medical Homes' Help Kids Get Comprehensive Care 3Health News:Study identifies therapeutic target for liver cancer and predictive biomarker of response 2Health News:Study identifies therapeutic target for liver cancer and predictive biomarker of response 3
... been designed as a compact, cost-effective and ... private clinics or as a second system. ... most commonly required investigations such as Uroflowmetry, ... Add-on options are available for Urethral Pressure ...
A compact mobile System Cart gives mobility within your department. The cart accomodates the Uromac Median data processor, desktop computer, printer and provides stowage space. Patient related transd...
... Aquarius TT™ offers the ultimate research ... the most knowledgeable clinician and researcher today. ... a system to meet your desired footprint ... panels to display live data both in ...
... Advanced diagnostic capabilities combined with ease of ... product in its class. Ideal for office ... complete system for Uroflowmetry, cystometry, leak point ... configurations are available which make the OM-5 ...
Medicine Products: